Do analysts rate EBON or FOXX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ebang International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Foxx Development 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, EBON or FOXX?

Foxx Development has higher revenue and earnings than Ebang International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ebang International $6.54M 2.04 -$14.09M N/A N/A Foxx Development $59.54M 0.30 -$9.02M -$6.87 N/A

Is EBON or FOXX more profitable?

Ebang International has a net margin of 0.00% compared to Foxx Development's net margin of -79.80%. Company Net Margins Return on Equity Return on Assets Ebang International N/A N/A N/A Foxx Development -79.80% N/A -59.35%

Do analysts prefer EBON or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ebang International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, EBON or QCLS?

Mymd Pharmaceuticals has lower revenue, but higher earnings than Ebang International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ebang International $6.54M 2.04 -$14.09M N/A N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is EBON or QCLS more profitable?

Ebang International's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ebang International N/A N/A N/A Mymd Pharmaceuticals N/A -76.40% -35.10%

Does the media prefer EBON or QCLS?

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Ebang International. MarketBeat recorded 3 mentions for Mymd Pharmaceuticals and 2 mentions for Ebang International. Ebang International's average media sentiment score of 0.93 beat Mymd Pharmaceuticals' score of 0.00 indicating that Ebang International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ebang International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AIMD or EBON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ebang International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, AIMD or EBON?

Ebang International has higher revenue and earnings than Ainos. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $13.60K 803.55 -$14.77M -$2.52 N/A Ebang International $6.54M 2.04 -$14.09M N/A N/A

Does the media refer more to AIMD or EBON?

In the previous week, Ainos had 1 more articles in the media than Ebang International. MarketBeat recorded 3 mentions for Ainos and 2 mentions for Ebang International. Ebang International's average media sentiment score of 0.93 beat Ainos' score of 0.17 indicating that Ebang International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ainos 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ebang International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer EBON or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ebang International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, EBON or TNFA?

Ebang International has higher revenue and earnings than TNF Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ebang International $6.54M 2.04 -$14.09M N/A N/A TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A

Is EBON or TNFA more profitable?

Ebang International's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ebang International N/A N/A N/A TNF Pharmaceuticals N/A -69.21% -33.98%

Do analysts recommend EBON or AGMH?

AGM Group has a consensus price target of $5.77, indicating a potential upside of 429.36%. Given AGM Group's higher possible upside, analysts plainly believe AGM Group is more favorable than Ebang International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ebang International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, EBON or AGMH?

AGM Group has higher revenue and earnings than Ebang International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ebang International $6.54M 2.04 -$14.09M N/A N/A AGM Group $30.56M 0.12 $560K N/A N/A

Is EBON or AGMH more profitable?

Company Net Margins Return on Equity Return on Assets Ebang International N/A N/A N/A AGM Group N/A N/A N/A

Does the media refer more to EBON or AGMH?

In the previous week, AGM Group had 1 more articles in the media than Ebang International. MarketBeat recorded 3 mentions for AGM Group and 2 mentions for Ebang International. Ebang International's average media sentiment score of 0.93 beat AGM Group's score of 0.63 indicating that Ebang International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ebang International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AGM Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ebang International (EBON) Competitors

$2.04 -0.03 (-1.45%)

Closing price 08/11/2026 03:58 PM Eastern

Extended Trading

$2.09 +0.05 (+2.65%)

As of 04:09 AM Eastern

Compare

EBON vs. FOXX, QCLS, AIMD, TNFA, and AGMH

Should you buy Ebang International stock or one of its competitors? Ebang International's main competitors and comparable companies include Foxx Development (FOXX), Mymd Pharmaceuticals (QCLS), Ainos (AIMD), TNF Pharmaceuticals (TNFA), and AGM Group (AGMH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "technology hardware, storage & peripherals" industry.

How does Ebang International compare to Foxx Development?

Ebang International (NASDAQ:EBON) and Foxx Development (NASDAQ:FOXX) are both small-cap technology companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ebang International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Foxx Development	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Ebang International and Ebang International both had 2 articles in the media. Foxx Development's average media sentiment score of 1.44 beat Ebang International's score of 0.93 indicating that Foxx Development is being referred to more favorably in the news media.

Company	Overall Sentiment
Ebang International	Positive
Foxx Development	Positive

1.1% of Ebang International shares are held by institutional investors. Comparatively, 60.4% of Foxx Development shares are held by institutional investors. 25.4% of Ebang International shares are held by insiders. Comparatively, 31.6% of Foxx Development shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ebang International has a net margin of 0.00% compared to Foxx Development's net margin of -79.80%.

Company	Net Margins	Return on Equity	Return on Assets
Ebang International	N/A	N/A	N/A
Foxx Development	-79.80%	N/A	-59.35%

Ebang International has a beta of 3, meaning that its share price is 200% more volatile than the broader market. Comparatively, Foxx Development has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market.

Foxx Development has higher revenue and earnings than Ebang International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ebang International	$6.54M	2.04	-$14.09M	N/A	N/A
Foxx Development	$59.54M	0.30	-$9.02M	-$6.87	N/A

Summary

Foxx Development beats Ebang International on 5 of the 9 factors compared between the two stocks.

How does Ebang International compare to Mymd Pharmaceuticals?

Ebang International (NASDAQ:EBON) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Ebang International's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ebang International	N/A	N/A	N/A
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Mymd Pharmaceuticals has lower revenue, but higher earnings than Ebang International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ebang International	$6.54M	2.04	-$14.09M	N/A	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

1.1% of Ebang International shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 25.4% of Ebang International shares are owned by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ebang International has a beta of 3, indicating that its share price is 200% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Ebang International. MarketBeat recorded 3 mentions for Mymd Pharmaceuticals and 2 mentions for Ebang International. Ebang International's average media sentiment score of 0.93 beat Mymd Pharmaceuticals' score of 0.00 indicating that Ebang International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ebang International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ebang International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Ebang International beats Mymd Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Ebang International compare to Ainos?

Ainos (NASDAQ:AIMD) and Ebang International (NASDAQ:EBON) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Ainos had 1 more articles in the media than Ebang International. MarketBeat recorded 3 mentions for Ainos and 2 mentions for Ebang International. Ebang International's average media sentiment score of 0.93 beat Ainos' score of 0.17 indicating that Ebang International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ainos	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ebang International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ainos has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, Ebang International has a beta of 3, indicating that its stock price is 200% more volatile than the broader market.

1.1% of Ebang International shares are owned by institutional investors. 9.8% of Ainos shares are owned by company insiders. Comparatively, 25.4% of Ebang International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ebang International has higher revenue and earnings than Ainos.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$13.60K	803.55	-$14.77M	-$2.52	N/A
Ebang International	$6.54M	2.04	-$14.09M	N/A	N/A

Ebang International has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ebang International's return on equity of 0.00% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-217.50%	-67.87%
Ebang International	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ebang International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Ebang International beats Ainos on 9 of the 11 factors compared between the two stocks.

How does Ebang International compare to TNF Pharmaceuticals?

Ebang International (NASDAQ:EBON) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Ebang International has higher revenue and earnings than TNF Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ebang International	$6.54M	2.04	-$14.09M	N/A	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Ebang International's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ebang International	N/A	N/A	N/A
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

1.1% of Ebang International shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 25.4% of Ebang International shares are owned by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ebang International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Ebang International had 2 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 2 mentions for Ebang International and 0 mentions for TNF Pharmaceuticals. Ebang International's average media sentiment score of 0.93 beat TNF Pharmaceuticals' score of 0.00 indicating that Ebang International is being referred to more favorably in the media.

Company	Overall Sentiment
Ebang International	Positive
TNF Pharmaceuticals	Neutral

Ebang International has a beta of 3, indicating that its share price is 200% more volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Summary

Ebang International beats TNF Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

How does Ebang International compare to AGM Group?

Ebang International (NASDAQ:EBON) and AGM Group (NASDAQ:AGMH) are both small-cap technology companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

AGM Group has higher revenue and earnings than Ebang International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ebang International	$6.54M	2.04	-$14.09M	N/A	N/A
AGM Group	$30.56M	0.12	$560K	N/A	N/A

In the previous week, AGM Group had 1 more articles in the media than Ebang International. MarketBeat recorded 3 mentions for AGM Group and 2 mentions for Ebang International. Ebang International's average media sentiment score of 0.93 beat AGM Group's score of 0.63 indicating that Ebang International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ebang International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ebang International has a beta of 3, suggesting that its stock price is 200% more volatile than the broader market. Comparatively, AGM Group has a beta of 2.49, suggesting that its stock price is 149% more volatile than the broader market.

1.1% of Ebang International shares are owned by institutional investors. 25.4% of Ebang International shares are owned by company insiders. Comparatively, 34.9% of AGM Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Ebang International	N/A	N/A	N/A
AGM Group	N/A	N/A	N/A

AGM Group has a consensus price target of $5.77, indicating a potential upside of 429.36%. Given AGM Group's higher possible upside, analysts plainly believe AGM Group is more favorable than Ebang International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ebang International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

AGM Group beats Ebang International on 5 of the 9 factors compared between the two stocks.

Get Ebang International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EBON vs. The Competition

Export

Metric	Ebang International	Technology Hardware, Storage & Peripherals Industry	Technology Sector	NASDAQ Exchange
Market Cap	$13.55M	$109.93B	$29.77B	$12.96B
Dividend Yield	N/A	1.71%	2.73%	10.34%
P/E Ratio	N/A	29.23	74.95	25.05
Price / Sales	2.04	61.69	598.73	69.51
Price / Cash	N/A	20.27	51.24	50.42
Price / Book	0.05	7.85	9.25	6.18
Net Income	-$14.09M	$3.46B	$678.40M	$347.05M
7 Day Performance	10.87%	2.40%	1.40%	1.24%
1 Month Performance	-3.18%	0.88%	0.41%	-0.65%
1 Year Performance	-49.13%	86.91%	196.13%	20.12%

Ebang International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EBON Ebang International	1.4309 of 5 stars	$2.04 -1.4%	N/A	-50.4%	$13.55M	$6.54M	N/A	260	Gap Down
FOXX Foxx Development	1.4183 of 5 stars	$2.65 +4.3%	N/A	-61.9%	$17.89M	$59.54M	N/A	N/A	Short Interest Decrease Gap Down
QCLS Mymd Pharmaceuticals	0.3664 of 5 stars	$2.95 +0.7%	N/A	N/A	$12.21M	N/A	N/A	6
AIMD Ainos	0.3239 of 5 stars	$1.42 +0.7%	N/A	-54.6%	$12.02M	$13.60K	N/A	40	Short Interest Increase Gap Up
TNFA TNF Pharmaceuticals	N/A	$2.93 +6.5%	N/A	-74.3%	$5.41M	N/A	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EBON) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ebang International (EBON) Competitors

EBON vs. FOXX, QCLS, AIMD, TNFA, and AGMH

How does Ebang International compare to Foxx Development?

Summary

How does Ebang International compare to Mymd Pharmaceuticals?

Summary

How does Ebang International compare to Ainos?

Summary

How does Ebang International compare to TNF Pharmaceuticals?

Summary

How does Ebang International compare to AGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBON vs. The Competition

Ebang International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ebang International (EBON) Competitors

EBON vs. FOXX, QCLS, AIMD, TNFA, and AGMH

How does Ebang International compare to Foxx Development?

Do analysts rate EBON or FOXX?

Does the media favor EBON or FOXX?

Do insiders and institutionals hold more shares of EBON or FOXX?

Is EBON or FOXX more profitable?

Which has more volatility and risk, EBON or FOXX?

Which has stronger earnings and valuation, EBON or FOXX?

Summary

How does Ebang International compare to Mymd Pharmaceuticals?

Is EBON or QCLS more profitable?

Which has better earnings and valuation, EBON or QCLS?

Do institutionals and insiders hold more shares of EBON or QCLS?

Which has more volatility and risk, EBON or QCLS?

Does the media prefer EBON or QCLS?

Do analysts prefer EBON or QCLS?

Summary

How does Ebang International compare to Ainos?

Does the media refer more to AIMD or EBON?

Which has more volatility & risk, AIMD or EBON?

Do institutionals and insiders have more ownership in AIMD or EBON?

Which has better valuation & earnings, AIMD or EBON?

Is AIMD or EBON more profitable?

Do analysts recommend AIMD or EBON?

Summary

How does Ebang International compare to TNF Pharmaceuticals?

Which has better valuation & earnings, EBON or TNFA?

Is EBON or TNFA more profitable?

Do institutionals and insiders believe in EBON or TNFA?

Do analysts prefer EBON or TNFA?

Does the media prefer EBON or TNFA?

Which has more risk and volatility, EBON or TNFA?

Summary

How does Ebang International compare to AGM Group?

Which has better valuation and earnings, EBON or AGMH?

Does the media refer more to EBON or AGMH?

Which has more volatility & risk, EBON or AGMH?

Do insiders and institutionals believe in EBON or AGMH?

Is EBON or AGMH more profitable?

Do analysts recommend EBON or AGMH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBON vs. The Competition

Ebang International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools